Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20230034917ION CHANNEL MODULATORS
US 02.02.2023
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 17780042 Applicant Praxis Precision Medicines, Inc. Inventor Kiran REDDY

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

2.20230037103USE OF A COMPOUND OF 4-(3-ETHOXY-4-HYDROXYPHENYL) ALKYL KETONE TYPE AGAINST BACTERIA OF THE BURKHOLDERIA CEPACIA COMPLEX
US 02.02.2023
Int.Class C07C 49/185
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
49Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
04Saturated compounds containing keto groups bound to acyclic carbon atoms
185containing -CHO groups
Appl.No 17778216 Applicant L’OREAL Inventor Sylvie CUPFERMAN

The present invention relates to the use of compounds of formula (I) in the treatment of products, in particular of aqueous or nonaqueous compositions, preferably water and aqueous compositions, against bacteria of the Burkholderia cepacia complex (Bcc), and also the use thereof in a process for treating an aqueous composition or water with respect to strains of the Bcc complex.

embedded image

formula (I) wherein:

    • R2 represents a hydrogen atom or a methyl or ethyl radical;
    • R3 represents a linear C1-C12 alkyl radical (saturated), optionally substituted with a hydroxyl group; or a linear C2-C12 alkenyl radical (C═C unsaturated), optionally substituted with a hydroxyl group.

3.20230029594BODY FAT REDUCING AGENT AND METHOD FOR SCREENING FOR SUBSTANCE CAPABLE OF REDUCING BODY FAT
US 02.02.2023
Int.Class C12Q 1/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
Appl.No 17788524 Applicant OSAKA UNIVERSITY Inventor Shizuo AKIRA

The present invention provides a body fat reducing agent comprising a Regnase-1 inhibitor as an active ingredient, and a method for screening for a substance capable of reducing body fat, the method comprising selecting a substance capable of inhibiting the expression of Regnase-1 or a substance capable of inhibiting the function of Regnase-1. The body fat reducing agent of the present invention is useful for improving metabolic syndrome, and for preventing and/or treating fatty liver disease, including nonalcoholic steatohepatitis (NASH). The screening method of the present invention can be used to identify a useful substance capable of reducing body fat.

4.20230030983FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US 02.02.2023
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 17655519 Applicant ASTEX THERAPEUTICS LTD Inventor Jayaprakash KARKERA

Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.

5.102022119036ORGANISCHE ELEKTROLUMINESZIERENDE VERBINDUNG, MEHRERE WIRTSMATERIALIEN UND DIESE UMFASSENDE ORGANISCHE ELEKTROLUMINESZIERENDE VORRICHTUNG
DE 02.02.2023
Int.Class C07D 421/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
421Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No 102022119036 Applicant Rohm And Haas Electronic Materials Korea Ltd. Inventor Jun Ji-Song

Die vorliegende Offenbarung betrifft eine organische elektrolumineszierende Verbindung, ein organisches elektrolumineszierendes Material und eine dieses umfassende organische elektrolumineszierende Vorrichtung, mehrere Wirtsmaterialien, die mindestens ein erstes Wirtsmaterial und mindestens ein zweites Wirtsmaterial umfassen, und eine organische elektrolumineszierende Vorrichtung, die diese umfasst. Durch Einbeziehung der Verbindung gemäß der vorliegenden Offenbarung als einziges Wirtsmaterial oder als mehrere Wirtsmaterialien kann eine organische elektrolumineszierende Vorrichtung mit verbesserter Treiberspannung, Lichtausbeute und/oder Lebensdauer im Vergleich zu den herkömmlichen organischen elektrolumineszierenden Vorrichtungen hergestellt werden.

6.20230033215SYSTEM AND METHOD FOR ENHANCED ETHANOL PRODUCTION
US 02.02.2023
Int.Class C07C 29/84
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
29Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
74Separation; Purification; Stabilisation; Use of additives
76by physical treatment
80by distillation
84by extractive distillation
Appl.No 17875197 Applicant ICM, Inc. Inventor David VanderGriend

A system for producing ethanol comprises a rectifier column that receives a first process stream comprising from about 42% to about 60% ethanol, wherein the rectifier column purifies the first process stream to provide an ethanol product stream that is at least about 90% ethanol, and one or more evaporators configured to evaporate water from a second process stream, wherein the one or more evaporators generate vapor, and wherein at least a portion of the vapor supplies heat energy for separation of ethanol from water in the rectifier column.

7.20230033537METHOD OF PRODUCING ADM COLLAGEN FIBER, ADM COLLAGEN FIBER PRODUCED USING METHOD, AND APPARATUS FOR PRODUCING ADM COLLAGEN FIBER
US 02.02.2023
Int.Class C07K 14/78
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
Appl.No 17792608 Applicant GENEWEL CO., LTD. Inventor Hong Doo KIM

The present invention relates to a method of producing an ADM collagen fiber, an ADM collagen fiber produced using the method, and an apparatus for producing the ADM collagen fiber. More particularly, the present invention relates to a method of producing an ADM collagen fiber including a step of extruding an acidic ADM collagen solution into a basic solution to form filaments. The present invention has an effect of providing a method of producing an ADM collagen fiber, an ADM collagen fiber produced using the method, and an apparatus for producing the ADM collagen fiber. According to the present invention, since a collagen solution raw material having a required concentration may be prepared by immediately pulverizing ADM collagen shells, economic efficiency and productivity may be increased through reduction in production cost and time. In addition, mass production is possible by using a continuous process apparatus with a simple structure.

8.WO/2023/006019POLYSUBSTITUTED BENZENE PD-L1 INHIBITOR, COMPOSITION AND USE THEREOF
WO 02.02.2023
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2022/108538 Applicant HANGZHOU HEALZEN THERAPEUTICS CO., LTD. Inventor WU, Yizhe
Disclosed in the present invention are a polysubstituted benzene PD-L1 inhibitor, a composition and the use thereof. The compound has a structure as represented by general formula (I). The inventor of the present invention confirmed by means of an experiment that the compound of the present invention exhibits a strong PD-1/PD-L1 blocking activity and a significant PD-L1 occupancy activity, and can reverse a PD-L1-inhibited T cell function. Moreover, the compound of the present invention can be orally absorbed, has a good pharmacokinetic property, and has a good anti-tumor inhibitory activity in vivo. Thus, the compound of the present invention can be used alone or in combination with other drugs in the treatment of diseases, disorders or conditions which would benefit from the inhibition of PD1 or PD-L1 activity, including infectious diseases, immune diseases, inflammatory diseases and cancers.
9.WO/2023/006499PROCESS FOR THE CONTINUOUS DISTILLATION OF ACRYLATES
WO 02.02.2023
Int.Class B01D 3/32
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
DSEPARATION
3Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
14Fractional distillation
32Other features of fractionating columns
Appl.No PCT/EP2022/070157 Applicant BASF SE Inventor GIESHOFF, Tile
Disclosed is a process for the continuous distillation of acrylates by means of a rectification column, characterized in that the acrylate concentration in the feed line of the rectification column is at least 80 wt%, the liquid in the bottom region of the rectification column is heated by an evaporator, and the evaporator parts in contact with the product are made of stainless steel.
10.WO/2023/006919HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF
WO 02.02.2023
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
Appl.No PCT/EP2022/071275 Applicant INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Inventor HENNINO, Ana
The tumoral stroma evolution during cancer is playing a key role as it may acts as a physical barrier limiting access of the immune cells to the tumor. Thus, βig-h3 (TGFβi) overexpression in the stroma is of bad prognosis in Pancreatic Ductal Adenocarcinoma and in other cancers. A monoclonal antibody against βig-h3 protein called 18B3 was shown playing a role in directly modulating the anti-tumoral immune response by blocking inhibiting CD8+ T cell activation. From 18B3 the inventors developed humanized antibodies having unexpectedly high affinity, slow dissociation rate and strong thermal stability making them powerful candidates for treating cancers wherein the stroma expresses βig-h3 in vivo. The invention thus relates to these humanized monoclonal antibodies and methods of treatment of such cancers.